Professional Documents
Culture Documents
JETIR1901148
JETIR1901148
JETIR1901148
org (ISSN-2349-5162)
Abstract: Each year approximately 16 million people worldwide affected by Whooping cough or pertussis. Pertussis, also known
as 100 day cough, is a highly infectious bacterial airborne disease caused by the bacteria Bordetella pertussis. Pertussis spreads
effortlessly through the cough and sneeze of a contaminated person. Most cases happen in the creating scene and individuals of
any age might be influenced. Virtually 2% of infected children less than a year of age depart this life. The chief method of
prevention for pertussis is immunization with the pertussis vaccine. There is deficient evidence to determine the effectiveness of
antibiotics in those who have been exposed but are lacking of symptoms. There are diverse therapeutic approaches available
worldwide for the management of whooping cough (pertussis) such as Acupuncture therapy, Naturopathic therapy, Therapy of
Gurah, Homeopathic therapy, Ayurvedic therapy and Allopathic therapy. The Naturopathic therapy involves Bellflower,
Kamakasturi, Syrup of garlic, Ginger, Syrup of radish and honey and Almond oil. The Homeopathic therapy involves various
remedies such as Arnica, Arsenicum, Belladonna, Bryonia, Carbo veg, Causticum, Chamomilla, Coccus desert flora, Cuprum,
Drosera, Hepar, Ipecac, Lachesis, Mercurius, Nux vom, Pulsatilla, Sepia and Squilla. The Ayurvedic therapy involves various
preparations such as Pippali, Aloe Vera Juice, Alfalfa Leaves, Comfrey, Almond Oil, Honey, Ginger, Calamus, Liquorice, Castor
Oil, Onion, Grapes, Turmeric, Belleric Myrobalan, Raisins, Aniseed, Cinnamomum Camphora, Pongamia Pinnata, Guggulu and
Home Remedies like Orange juice and water, All-fruit diet, Warm-water enema. The Allopathic therapy predominantly involves
Macrolide group of antibiotics such as Clarithromycin, Azithromycin and Erythromycin. There are various health governing
bodies and organizations around the world, provides treatment guidelines for the management of whooping cough (pertussis).
Index Terms - Pertussis, Bordetella pertussis, Acupuncture, Naturopathic therapy, Therapy of Gurah, Clarithromycin,
Azithromycin, Erythromycin.
I. INTRODUCTION
Whooping cough or Pertussis, also known as 100 day cough, is a highly infectious bacterial airborne disease caused by the
bacteria Bordetella pertussis (Carbonetti, 2007). Pertussis spreads effortlessly through the cough and sneeze of a contaminated
person (Pertussis Causes & Transmission.cdc.gov., September 4, 2014. Retrieved 12 February 2015.
http://www.cdc.gov/pertussis/about/causes-transmission.html).
Primarily symptoms are usually related to those of the ordinary cold with a runny nose, fever and mild cough. This is then
trailed by significant lots of genuine hacking fits. Following a fit of coughing a high-pitched whoop sound or gasp may occur as the
person breathes in (Pertussis Signs & Symptoms.cdc.gov., May 22, 2014. Retrieved 12 February 2015.
http://www.cdc.gov/pertussis/about/signs-symptoms.html). The coughing may last for more than a hundred days or ten weeks
(Pertussis Fast Facts cdc.gov., February 13, 2014. Retrieved 12 February 2015. http://www.cdc.gov/pertussis/fast-facts.html). A
person may cough so hard they vomit, break ribs, or become very tired from the effort (Pertussis Complications. cdc.gov. 2013).
The period of time between infection and the onset of symptoms is usually seven to ten days (Atkinson and William, 2012).
Disease may occur in those who have been vaccinated but symptoms are typically milder (Pertussis Signs & Symptoms.cdc.gov.,
May 22, 2014. Retrieved 12 February 2015. http://www.cdc.gov/pertussis/about/signs-symptoms.html).
The determination is done by gathering a sample from the back side of the nose and throat. Then either culture or polymerase
chain reaction can be used for sample testing (Pertussis Specimen Collection.cdc.gov., August 28, 2013. Retrieved 13 February
2015. http://www.cdc.gov/pertussis/clinical/diagnostic-testing/specimen-collection.html).
Every year around 16 million people worldwide affected by pertussis (Wang et al., 2014). Most cases occur in the developing
world and people of all ages may be affected (Heininger U., 2010). In 1990 it resulted in 138,000 deaths occurred and now 61,000
deaths in 2013 (GBD 2013 Mortality and Causes of Death, Collaborators. Lancet, 17 December 2014,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340604/). Virtually 2% of infected children less than a year of age depart this life.
In 16th century the outbreaks of the disease were first described and in 1906 the bacteria Bordetella pertussis was discovered. The
vaccine became offered in the 1940s (Pertussis Signs & Symptoms.cdc.gov., May 22, 2014. Retrieved 12 February 2015.
http://www.cdc.gov/pertussis/about/signs-symptoms.html).
The chief method of prevention for pertussis is immunization with the pertussis vaccine. There is deficient evidence to
determine the effectiveness of antibiotics in those who have been exposed but are lacking of symptoms (Altunaiji et al., 2007).
II. THERAPEUTIC APPROACHES FOR THE MANAGEMENT OF WHOOPING COUGH (PERTUSSIS)
1. Acupuncture therapy
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 382
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
Acupuncture therapy has provided excellent results against whooping cough (pertussis). In the year 1996, Yao and his
associates had organized a study of Acupuncture therapy in a randomized controlled trial design with a ratio of 145:50. The test
group was on Acupuncture at bāxié (EX-UE9) and the Control Group was on Chloramphenicol intravenous drip.
The results were extraordinary ones. After 7 days of treatment, 98.6% cure from pertussis was observed in the test group whereas
10% cure from pertussis was observed in the control group. (Yao et al., 1996)
2.2 Bellflower
Bellflower is used as a natural herb for the treatment of whooping cough. Bellflower is resourcefully available by the
roots of Platycodon grandiflorus, belongs from Campanulaceae family. Triterpene saponins are the active chemical constituents
of Bellflower. Therapeutically Bellflower is used for expectorant, antitussive (Tripathi KD. 2008), tonsillitis, pertussis, asthma,
anti inflammatory, anti ulcer, anti cholestraenemia. (Meenakshi et al 2011)
2.3Kamakasturi
Kamakasturi is also used as a natural herb for the treatment of whooping cough. Kamakasturi is resourcefully available
by Ocimum basilicum L, belongs from Lamiaceae family. In Krishna district of Andhra Pradesh (India), 10-15 ml of leaf extract
of Kamakasturi is given orally to cure whooping cough. (B. Siva Kumari et al 2014)
2.4.2 Ginger
Ginger (adrak) is another effective remedy for whooping cough. A teaspoon of new ginger juice, blended with some
fenugreek (methi) decoction and nectar to taste, is a magnificent diaphoretic. It goes about as an expectorant in this infection.
(Health Education Library For People. http://www.healthlibrary.com, 5/19/1999)
3. Therapy of Gurah
The traditional system of medicine in Indonesia involves therapy of Gurah for the treatment of whooping cough
(pertussis). Gurah is a therapeutic technique that uses special extracts of herbs to clear the nasal cavity and pharynx of mucus. The
gurah method is very simple. The healer instills a special liquid into the patient’s nostrils. The liquid is prepared by the healer and
contains certain herbs, of which the common ones are Srigunggu (Clerodendron javanicum) or Awar-awar (Ficus septica) leaves
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 383
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
and turmeric. Honey is also used. The extracts of the herbs are diluted to a weak concentration. The patient lies supine with the
neck bent backward. The liquid is then instilled into the nostrils for about three to five minutes through a funnel made of banana
leaves.
The composition of ingredients is adjusted according to the patient’s condition. The process heats up the nasal cavity and the
mucus flows out automatically. When the mucus is being discharged, the patient has to either sit up or lie on his stomach. He
remains in that position until the mucus stops dripping. This therapy is often combined with jamu remedies, and sometimes with
massage. (Masruri. The secret of gurah therapy, 2000), (Ranjit Roy et al, 2001)
4. Homeopathic therapy
4.1 Homeopathy has been utilized for more than 100 years to effectively treat patients experiencing challenging hack, otherwise
called pertussis. With challenging hack cases in the U.S. ascending at what the CDC depicts as "a disturbing rate" - it is
advantageous to allude to the old ace, Henry Guernsey M.D. to take a gander at a portion of the solutions for considering for
patients with this condition.
Arnica: Every coughing spell is announced with crying.
Arsenicum: When there is extraordinary surrender with waxy pallor and frigidity of the skin.
Belladonna: The tyke gets extremely red in the face with each hacking spell.
Bryonia: Worse movement. Hack more regrettable subsequent to eating or drinking with spewing.
Carbo veg: Great weariness after each hacking spell, with blueness of the skin, hot head and face. The patient needs to be fanned.
Causticum: An extremely dry hack remains quite a while. Does not get totally well.
Chamomilla: A cough is dry; the child is very fretful, must be carried to be appeased, one red cheek.
Coccus desert flora: Every hacking spell is ended by spitting of substantial amounts of ropy bodily fluid.
Cuprum: With each hacking fit, the kid hacks itself into a cataleptic fit - it shows up as though the youngster were dead.
Drosera: When the tyke is more terrible, especially after 12 AM, with high fever, hack in brutal uncontrollable spells as though it
would choke, in some cases seeping at the nose and mouth.
Hepar: When a cough seems complicated with croup; worse towards morning; a cough sounds croupy and it seems as if the
patient would choke.
Ipecac: Strangling with a cough till blue in the face.
Lachesis: Child dependably stirs in a hacking fit; it appears to exceptionally swoon and powerless.
Mercurius: The kid sweats especially around evening time and can seep from nose and mouth with each hacking spell. Either by
day just or by night just, the tyke dependably has twofold hacking spells, which are isolated by interims of impeccable rest.
Nux vom: Hard dry hack with obstruction. More awful after 4:00 PM. The kid ends up blue in the face and seeps from the nose
and mouth.
Pulsatilla: Child weepy. A cough very loose, with vomiting of mucus, diarrhoea, a cough worse at night.
Sepia: A cough always much worse in the morning when it is loose and terminates in an effort to vomit.
Squilla: During a cough the child sneezes, waters at the eyes and nose; the child constantly rubs its eyes, nose and face with its
fists during a cough. (National Center for Homeopathy. http://nationalcenterforhomeopathy.org/content/accelerating-the-healing-
of-bone-fracture-usinghomeopathy-a-prospective-randomized-double-b 27 November 2014), (National Center for Homeopathy.
www.nationalcenterforhomeopathy.org/content/whooping-cough-back-in-the-news-homeopathycan-, 27 November 2014)
4.2 According to Dr.Didier Grandgeorge, The homeopathic treatment of whooping & hacking cough is not always easy. It
involves several homeopathic medications such as:
• Drosera 30CH
• Carbo Vegetalis 30CH
• Corallium Rubrum 7CH
• Natrum Muriaticum 15CH
• Squilla Maritima 7 CH
• Cuprum Metallicum 9CH
• Sanguinaria Canadensis 9CH
• Pertussinum 30CH (Dr .Didier Grandgeorge, Homeopathic treatment of Cough, 27 November 2014)
4.3 F. Humphreys, M.D., has given his homeopathic treatment recommendations in the homeopathic manual, 1884. When
children have been exposed, or begin to cough, give simply three pellets of Specific No. Twenty, four times per day. (F.
Humphreys, M.D.,1884)
Homeopathic remedy no. Twenty Cures Whooping-Cough (given early, this Specific arrests the development of the Cough, and
given at any stage, allays the irritation, moderates a cough, and winds up the disease), Old, Violent, Spasmodic, or Convulsive
Coughs. Price, 50c. per Large Vial; 1oz., $l.OO. (F. Humphreys, M.D, 1884)
4.4 According to the homeopathic remedy prescriber the treatment for whooping cough involves:
4.4.1 Drosera can be given as a homeopathic remedy in the condition and symptoms like Persistent, irritating cough coming from
deep down in chest, occasionally leading to vomiting, Whooping cough. Worse lying down, after midnight
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 384
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
4.4.2 Ignatia can be given as a homeopathic remedy in the condition and symptoms like Dry, hacking, spasmodic. The more
amounts of a cough then more irritation, whooping cough. Unable to take a full breath. Sigh frequently (Health and Homeopathy.
www.healthandhomeopathy.com, 10/12/2018)
4.5.1 Homecare:
• Increase your water intake.
• Boil water with freshly cut ginger and add lemon and honey (ginger: to break down and expel mucus; lemon: rich in Vitamin C;
honey: antibacterial & antiviral and soothes a sore throat)
• Drink heated water with apple juice vinegar and a sprinkle of cayenne pepper. (Cayenne pepper is extremely warming and
wealthy in Vitamin C)
• Eat and drink just warming sustenance. In the event that you eat cool or frosty sustenance or beverages, it might debilitate your
resistant framework and make a more serious hack.
• Get bunches of rest and rest
• Continue with moderate, delicate exercise or stretch to encourage the development of lymph, just in the event that you typically
work out (except if you have a fever!!!). Anyway now isn't an ideal opportunity to begin working out.
• Take a hot shower (Don't wet your hair or remain in for a really long time) and afterward envelop with covers to sweat the
pathogen out of your framework.
5. Ayurvedic therapy
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 385
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
(1) Pippali powder is indicated for an acute and chronic cough due to a common cold, pharyngitis, laryngitis, bronchitis, naso-
respiratory catarrh, respiratory allergy, asthma and smoking.
(2) A non-specific cough is adequately manageable with Pippali Churna.
(3) The definition is likewise viable in controlling manifestations related with a hack like wheezing, hiccough, nasal release,
fever, poor hunger, heartburn, and so forth. (Sharma PC et al., 2001)
5.4 Comfrey
Take a comfrey tea for dry persistent coughs. The comfrey should not be taken for long-term use as it may cause liver
damage.
5.6 Honey
Add a tablespoon of honey to a glass of boiling water and drink as needed. This will give a calming impact to the
throat and will fix challenging hack quick.
5.7 Ginger
10ml of ginger juice with an equal quantity of honey may provide relief to whooping cough, you may take it two times
daily.
5.8 Calamus
A pinch of the powder of the roasted calamus can be given with a teaspoon of honey. This will give alleviation in
challenging hack to the patient. Being antispasmodic, it forestalls serious episodes of hacking. For littler youngsters, the portion
must be proportionately littler.
5.10 Liquorice
Root gives soothing to your throat and contains anti-inflammatory properties, and is an expectorant. Try not to utilize
on the off chance that you have hypertension.
5.12 Onion
Syrup prepared by combining 1 tablespoon raw onion juice with 1 tablespoon of honey is very beneficial for curing
whooping cough. Take 1 teaspoon of it daily. The utilization of crude onion is important in a hack. This vegetable ought to be
cleaved fine and the juice removed from it. One teaspoon of the juice should then be blended with one teaspoon of nectar and kept
for four or five hours-it will make a superb hack syrup and ought to be taken twice every day. Onions are additionally valuable in
expelling mucus. A medium-sized onion ought to be pulverized, the juice of one lemon added to it, and after that some bubbling
water poured on it. A teaspoon of nectar can be included for taste. This cure ought to be taken a few times each day. (Ayurvedic
treatment of Whooping Cough. https://ayurvedatreatments.co.in/ayurvedatreatments/index.php/ayurvedic-treatments/479-
whooping-cough-and-its-ayurvedic-treatment, 11/11/2018)
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 386
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 387
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
6. Allopathic treatment
Thinking about microbiological leeway and reactions, three days of azithromycin or seven days of clarithromycin are the best
regimens. Seven days of trimethoprim/sulfamethoxazole additionally seemed, by all accounts, to be viable for the destruction of
B. pertussis from the nasopharynx and may fill in as an elective anti-microbial treatment for patients who can't endure macrolides.
There is lacking proof to decide the advantage of prophylactic treatment of pertussis contacts. (Altunaiji S, Kukuruzovic R, Curtis
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 388
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
N, Massie J., Antibiotics for whooping cough (pertussis). https://www.ncbi.nlm.nih.gov/pubmed/15674946, PMID: 15674946
DOI: 10.1002/14651858.CD004404.pub2)
Cotrimoxazole is advised (off-license) where macrolides are contraindicated or not tolerated. Otherwise, management is
supportive and involves symptomatic relief. No symptomatic measures have yet been demonstrated powerful in clinical
preliminaries. (Wang K, et al 2014), (Whooping Cough, Dr Mary Harding, Document ID: 638 (v29), 6/12/2017
https://patient.info/in/doctor/whoopingcoughpro)
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 389
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
The one possible exception to antibiotic use discussed above is when pertussis infection is suspected in patients with acute
tracheobronchitis. Although studies have identified pertussis in up to 20% of patients with a cough longer than 2–3 weeks, there is
no specific clinical feature that identifies a persistent cough due to pertussis (Bergquist SO et al 1987)
This is especially true in adults where the classic features of whooping cough are not seen. In the setting of a familial or
community outbreak of B. pertussis infection, a high index of suspicion is required and early institution of the appropriate
antibiotics can shorten the duration of transmission of this highly infectious condition by decreasing the shedding of the organism.
The most broadly utilized anti-toxin for this disease is erythromycin at 30– 40mg/kg each 6h for about fourteen days.
Nevertheless, there is no evidence to indicate that the natural course of pertussis, including the duration of a cough, can be
significantly altered when the treatment is started 7–10 days after the onset of illness. (Bergquist SO et al 1987), (Sprauer MA et
al 1992),(Wirsing von Konig CH et al. 1998)
7.1 National Treatment Guidelines for Antimicrobial Use in Infectious Diseases 2016 (For pertussis treatment)
Erythromycin for 14 days, Azithromycin for 5 days, Clarithromycin for 7 days and have similar efficacy but differ
in terms of cost, duration of therapy, side effects, tolerability, a likelihood of drug interaction. Considering all factors,
Azithromycin in a dose of 10 mg/kg once a day for 5 days in infants less than 6 months and 10 mg/kg on day 1 and then 5 mg/kg-
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 390
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
day on 2 to 5 days is the cheapest, shortest best tolerated and most convenient option and can be safely given to infants less than 1
month (unlike all other macrolides). (National Treatment Guidelines for Antimicrobial Use in Infectious Diseases 2016,
Government of India)
7.2 Standard Treatment Guidelines for Medical Officers, 2003 (For pertussis treatment)
The challenging hack is a youth infection due to Bordetella pertussis. In poor living conditions, it can contribute to
malnutrition and to increased childhood mortality. This emphasizes the role of immunization. A few creators prescribe anti-
microbial treatment amid the catarrhal stage (as it were). Erythromycin (PO) to be given for 7 days dose or Chloramphenicol (PO)
dose, salbutamol 0.1 ml /kg/dose for a cough. During the paroxysmal stage, antibiotics are useless. Advise the mother to ensure
• Adequate hydration.
• To humidify air if possible.
• Above all to ensure adequate nutrition (continue breastfeeding and give supplements) in spite of the child’s anorexia and
vomiting.
• Advice the mother to feed the child after each fit of coughing associated with vomiting.
For secondary infections antibiotics (PO, 1M or IV depending on severity)- Amoxicillin (PO) Child : 50 mg/kg/ d divided into 2-3
doses x 5-10 days dose, Ampicillin (PO): 100 mg/kg/ d divided into 2-3 doses x 5-10 days Adult 500 mg every 4-6 hours; Child
under 10 years, half the adult dose or Chloramphenicol (PO) dose or Cotrimoxazole (PO) dose. Infants less than 3 months should
be admitted to hospital and observed continuously, because of a risk of apnoea or asphyxia. The prevention of whooping cough
(pertussis) can be achieved by immunization such as
• Immunization integrated into the Expanded Program on Immunization. A decent insurance requires 3 infusions, each something
like multi-month separated.
• The first year of life- three doses of anti-tetanus vaccine at 6, 10 and 14 weeks.
• Booster dose. In the Second year of life (at 18 months)
• Immunization of non-immune infants, who have been in contacts with pertussis cases and are not yet ill, will attenuate the
disease.
(Standard Treatment Guidelines for Medical Officers published: July 2003 Department of Health & Family Welfare, GOC with
Support of Chhattisgarh)
7.4 Standard Treatment Guidelines for pertussis, Republic of Ghana, Ministry of Health, Sixth Edition, 2010
Pertussis can be counteracted by the "Five of everyone" vaccination suggested for all youngsters. In the event of a
child developing pertussis before immunization, the “Five in One” vaccine should still be given to protect against the four other
diseases. During epidemics, or when there is a clear history of contact in a child with catarrh, antibiotics may help reduce the
period of infectivity and reduce transmission. The treatment of pertussis involves Erythromycin, oral, Adults 500 mg 6 hourly for
7 days, whereas for Children 8-12 years; 250-500 mg 6 hourly for 7 days, 2-8 years; 250 mg of syrup 6 hourly for 7 days and < 2
years; 125 mg of syrup 6 hourly for 7 days.
The Non-pharmacological treatment involves
• Feed frequently between coughing spasms
• Encourage adequate oral fluid intake
• Admit to a hospital when complications like dehydration, fever, pneumonia and malnutrition arise.
• Allude babies who have a scene of apnoea (drawn out discontinuance of breathing) or of turning blue. (Standard Treatment
Guidelines for pertussis, Republic of Ghana, Ministry of Health, Sixth Edition, 2010)
7.5 Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis 2005 CDC
Guidelines
Keeping up high immunization inclusion rates among preschool kids, teenagers, and grown-ups and limiting
exposures of babies and people at high hazard for pertussis is the best method to counteract pertussis. Anti-microbial treatment of
pertussis and wise utilization of antimicrobial operators for postexposure prophylaxis will annihilate B. pertussis from the
nasopharynx of contaminated people (symptomatic or asymptomatic). A macrolide administered early in the course of illness can
reduce the duration and severity of symptoms and lessen the period of communicability (Bortolussi R et al. 1995). Approximately
80%90% of patients with untreated pertussis will spontaneously clear B. pertussis from the nasopharynx within 34 weeks from
onset of a cough (Kwantes W et al 1983); however, untreated and unvaccinated infants can remain culture positive for >6 weeks
(Henry R et al. 1981). Close asymptomatic contacts (Garner JS,1996) can be administered postexposure chemoprophylaxis to
prevent secondary cases; symptomatic contacts should be treated as cases.
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 391
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
Erythromycin, a macrolide anti-toxin, has been the antimicrobial of decision for treatment or postexposure prophylaxis of
pertussis. It is commonly controlled in 4 disengaged regular segments for 14 days. Although effective for treatment and
postexposure prophylaxis, erythromycin is accompanied by uncomfortable to distressing side effects that result in poor adherence
to the treatment regimen. All through the most recent decade, in vitro considers have affirmed the effectiveness against B.
pertussis of two other macrolide specialists like azithromycin and clarithromycin. (Hoppe JE, Eichhorn A.1989), (Kurzinsky TA
et al 1988),(Hoppe JE et al 1998), (Hardy DJ et al 1988), (Bannatyne RM et al 1982), (Mortensen JE et al 2000),
(DoucetPopulaire F et al 1997), (Felmingham D et al 1997). Results from in vitro examine are not generally duplicated in clinical
investigations and practice. A writing quest and audit was directed for in vivo examines and clinical preliminaries that were led
amid 1970-2004 and utilized clarithromycin or azithromycin for the treatment and prophylaxis of pertussis. Based on this audit,
rules were produced to widen the range of macrolide operators accessible for pertussis treatment and postexposure prophylaxis
and are introduced in this answer to refreshing past CDC suggestions (CDC. Rules for the control of pertussis flare-ups. Atlanta,
2000). Treatment and postexposure prophylaxis proposals are made based on existing logical proof and hypothetical justification.
Recommendations
A. Treatment- The macrolide specialists erythromycin, clarithromycin, and azithromycin are favoured for the treatment of
pertussis in people matured >1 month. For infants aged <1 month, azithromycin is preferred; erythromycin and clarithromycin are
not recommended. For treatment of persons aged >2 months, an alternative agent to macrolides is trimethoprim-sulfamethoxazole
(TMP-SMZ).
The decision of antimicrobial for treatment or prophylaxis should consider viability, security (counting the potential for
unfavourable occasions and medication cooperations), bearableness, simplicity of adherence to the routine endorsed, and cost.
Azithromycin and clarithromycin are as powerful as erythromycin for treatment of pertussis in people matured >6 months, are
better endured, and are related with less and milder reactions than erythromycin.
Erythromycin and clarithromycin, but not azithromycin, are inhibitors of the cytochrome P450 enzyme system (CYP3A subclass)
and can interact with other drugs that are metabolized by this system. Azithromycin and clarithromycin are more resistant to
gastric acid, achieve higher tissue concentrations, and have a longer half-life than erythromycin, allowing less frequent
administration (12 doses per day) and shorter treatment regimens (57 days). Erythromycin is offered as generic provision and is
significantly cheap than azithromycin and clarithromycin.
B. Postexposure prophylaxis- A macrolide can be managed as prophylaxis for close contacts of a man with pertussis if the
individual has no contraindication to its utilization. The choice to manage postexposure chemoprophylaxis is made in the wake of
considering the irresistibleness of the patient and the force of the presentation, the potential results of serious pertussis in the
contact, and conceivable outcomes for the auxiliary introduction of people at high hazard from the contact (e.g., babies matured
<12 months). For postexposure prophylaxis, the advantages of controlling an antimicrobial operator to lessen the hazard for
pertussis and its entanglements ought to be weighed against the potential unfavorable impacts of the medication. Organization of
postexposure prophylaxis to asymptomatic family unit contacts inside 21 days of the beginning of a hack in the list patient can
counteract symptomatic contamination.
Hacking (symptomatic) family unit individuals from a pertussis patient ought to be treated as though they have pertussis. Since
serious and once in a while deadly pertussis-related intricacies happen in babies matured <12 months, particularly among
newborn children matured <4 months, postexposure prophylaxis ought to be regulated in introduction settings that incorporate
newborn children matured <12 months or ladies in the third trimester of pregnancy. The suggested antimicrobial operators and
dosing regimens for postexposure prophylaxis are the equivalents as those for treatment of pertussis.
C. One of a kind contemplations for babies matured less than 6 months when utilizing macrolides for the executives or
postexposure prophylaxis-The U.S. Nourishment and Drug Administration (FDA) has not approved any macrolide for use in
infant youngsters developed less than 6 months. Data on the security and ampleness of azithromycin and clarithromycin use
among infant kids developed less than 6 months are limited.
Information from subsets of babies matured 15 months (selected in little clinical investigations) recommend the comparable
microbiologic adequacy of azithromycin and clarithromycin against pertussis likewise with more seasoned newborn children and
youngsters. If not treated, newborn children with pertussis remain culture positive for longer periods than more seasoned kids and
grown-ups (Riitta H,1982). This restricted information bolsters the utilization of azithromycin and clarithromycin as first-line
operators among newborn children matured 15 months, in light of their in vitro viability against B. pertussis, their exhibited
security, and viability in more established kids and grown-ups, and more advantageous dosing plan.
For the treatment of pertussis among newborn children matured <1 month (neonates), no information is accessible on the viability
of azithromycin and clarithromycin. Modified works and distributed case arrangement depicting the utilization of azithromycin
among babies matured <1-month report less antagonistic occasions contrasted and erythromycin (Friedman DS et al 2004); to
date, utilization of azithromycin in newborn children matured <1 month has not been related with childish hypertrophic pyloric
stenosis (IHPS). Subsequently, for pertussis, azithromycin is the favored macrolide for postexposure prophylaxis and treatment of
newborn children matured <1 month. In this age gathering, the danger of gaining extreme pertussis and its dangerous difficulties
exceed the potential hazard for IHPS that has been related to erythromycin (Honein MA et al 1999). Newborn children matured
<1 month who get a macrolide ought to be checked for IHPS and different genuine unfriendly occasions.
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 392
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
D. Safety- A thorough depiction of the wellbeing of the prescribed antimicrobials is accessible in the bundle embed, or in the
most recent release of the Red Book: Pharmacy's Fundamental Reference. A macrolide is contraindicated if there is a history of
hypersensitivity to any macrolide agent. Neither erythromycin nor clarithromycin ought to be managed correspondingly with
astemizole, cisapride, pimazole, or terfenadine. The most regularly revealed symptoms of oral macrolides are gastrointestinal
(e.g., sickness, regurgitating, stomach torment and spasms, looseness of the bowels, and anorexia) and rashes; reactions are more
continuous and extreme with erythromycin utilize.
A. Azithromycin-Azithromycin is accessible in the United States for oral intake as azithromycin dihydrate (suspension, tablets,
and containers). It is controlled as a solitary day by day portion.
Recommended Regimen:
• Infants aged <6 months: 10 mg/kg per day for 5 days.
• Infants and children aged >6 months: 10 mg/kg (maximum: 500 mg) on day 1, followed by 5 mg/kg per day (maximum: 250
mg) on days 25.
• Adults: 500 mg on day 1, followed by 250 mg per day on days 25.
• Reactions incorporate stomach inconvenience or agony, loose bowels, sickness, regurgitating, cerebral pain, and wooziness.
Azithromycin ought to be endorsed with an alert to patients with debilitated hepatic capacity. All patients ought to be forewarned
not to take azithromycin and aluminium or magnesium-containing acid neutralizers at the same time on the grounds that the last
decreases the rate of ingestion of azithromycin. Checking of patients is prompted when azithromycin is utilized correspondingly
with operators processed by the cytochrome P450 protein framework and with different medications for which the
pharmacokinetics change (e.g., digoxin, triazolam, and ergot alkaloids). Medication connections responses like those watched for
erythromycin and clarithromycin have not been accounted for. Azithromycin is delegated a FDA Pregnancy Category B sedate
(USFDA. Current categories for drug use in pregnancy. 2001)
B. Erythromycin- Erythromycin is accessible in the United States for the oral organization as erythromycin base (tablets and
containers), erythromycin stearate (tablets), and erythromycin ethylsuccinate (tablets, powders, and fluids). Because relapses have
been reported after completion of 710 days of treatment with erythromycin, a 14day course of erythromycin is recommended for
treatment of patients with pertussis or for postexposure prophylaxis of close contacts of pertussis patients (CDC. Diphtheria,
tetanus, and pertussis: recommendations for vaccine use and other preventive measures, 1991).
Recommended Regimen:
• Infants aged <1 month: not preferred because of risk for IHPS. Azithromycin is the recommended antimicrobial agent. If
azithromycin is unavailable and erythromycin is used, the dose is 4050 mg/kg per day in 4 divided doses. These infants should be
monitored for IHPS.
• Infants aged >1 month and older children: 4050 mg/kg per day (maximum: 2 g per day) in 4 divided doses for 14 days.
• Grown-ups: 2 g for every day in 4 isolated portions for 14 days
Gastrointestinal aggravation, including epigastric pain, stomach issues, queasiness, spewing, and loose bowels, is the most widely
recognized unfriendly impacts related with the oral organization of erythromycin. Side effects are portion related. A few details
with enteric covered tablets and the ester subsidiaries (e.g., ethylsuccinate) can be taken with sustenance to limit these symptoms.
Excessive touchiness responses (e.g., skin rashes, medicate fever, or eosinophilia), cholestatic hepatitis, and sensorineural hearing
misfortune have happened after an organization of macrolides; extreme responses, for example, hypersensitivity is uncommon.
An expanded hazard for IHPS has been accounted for in neonates amid the month after erythromycin organization. In one case,
pyloric stenosis happened in a breastfeeding newborn child whose mother took erythromycin. In 1999, a cluster of seven cases of
IHPS was reported among neonates (all aged <3 weeks when prophylaxis was started) who had taken erythromycin after exposure
to a pertussis patient. In a cohort study, erythromycin prophylaxis was causally associated with IHPS (seven cases out of 157
erythromycin exposed infants versus zero cases out of 125 infants with no erythromycin exposure (relative risk: infinity [95%
confidence interval = 1.7infinity]).
The high case fatality ratio of pertussis in neonates underscores the importance of preventing pertussis among exposed infants.
Healthcare providers who prescribe erythromycin rather than azithromycin to newborns should inform parents about the possible
risks for IHPS and counsel them about signs of IHPS.
Erythromycin is contraindicated if there is a history of hypersensitivity to any macrolide agent. Erythromycin should not be
administered concomitantly with astemizole, cisapride, pimazole, or terfenadine. Rare cases of serious cardiovascular adverse
events, including electrocardiographic QT/QTc interval prolongation, cardiac arrest, torsades de pointes, and other ventricular
arrhythmias, have been observed after concomitant use of erythromycin with these drugs.
Erythromycin is an inhibitor of the cytochrome P450 enzyme system (CYP3A subclass). Coadministration of erythromycin and a
drug that is primarily metabolized by CYP3A can result in elevations in drug concentrations that could increase or prolong both
the therapeutic and adverse effects of the concomitant drug. Drugs that are metabolized by CYP3A include alfentanil,
bromocriptine, cyclosporine, carbamazepine, cilostazol, disopyramide, dihydroergotamine, ergotamine, lovastatin and
simvastatin, methylprednisolone, quinidine, rifabutin, vinblastine, tacrolimus, triazolobenzodiazepines (e.g., triazolam and
alprazolam) and related benzodiazepines, and sildenafil. In addition, reports exist of drug interactions of erythromycin with drugs
not thought to be metabolized by CYP3A, including zidovudine, hexobarbital, phenytoin, and valproate, theophylline, digoxin,
and oral anticoagulants.
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 393
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
Erythromycin is classified as an FDA Pregnancy Category B drug (CDC. Diphtheria, tetanus, and pertussis: recommendations for
vaccine use and other preventive measures, 1991). Animal reproduction studies have failed to demonstrate a risk to the fetus, but
no adequate or well-controlled studies in humans exist.
C. Clarithromycin- Clarithromycin is accessible in the United States for the oral intake as granules for oral suspension and
tablets.
Recommended Regimen:
• Infants aged <1 month: not recommended.
• Infants and children aged >1 month: 15 mg/kg per day (maximum: 1 g per day) in 2 divided doses each day for 7 days.
• Grown-ups: 1 g for every day in two partitioned dosages for 7 days.
The most widely recognized unfriendly impacts related to clarithromycin incorporate epigastric pain, stomach issues, sickness,
heaving, and loose bowels. Extreme touchiness responses (e.g., skin rashes, tranquilize fever, or eosinophilia), hepatotoxicity, and
serious responses, for example, hypersensitivity are uncommon. Due to its comparability to erythromycin, both synthetically and
metabolically, clarithromycin ought not to be controlled to newborn children matured <1 month since it is obscure if the
medication can be comparatively connected with IHPS. The medication is contraindicated if there is a past filled with touchiness
to any macrolide specialist. Like erythromycin, clarithromycin ought not to be controlled correspondingly with astemizole,
cisapride, pimazole, or terfenadine. Clarithromycin represses the cytochrome P450 protein framework (CYP3A subclass), and
coadministration of clarithromycin and a medication that is fundamentally utilized by CYP3A can result in heights in medication
fixations that could increment or delay both the remedial and unfriendly impacts of the corresponding medication. Clarithromycin
can be controlled without measurement modification in patients with debilitated hepatic capacity and ordinary renal function;
However, sedate dose and an interim between portions ought to be reassessed within the sight of disabled renal capacity.
Clarithromycin is arranged by FDA as a Pregnancy Category C tranquilize (CDC. Diphtheria, lockjaw, and pertussis: suggestions
for immunization utilize and other preventive measures, 1991). Creature proliferation thinks about have demonstrated an
unfriendly impact on the fetus; no sufficient or all around controlled examinations in people exist.
D. Alternate agent (TMP-SMZ)- Records from scientific studies indicate that TMP-SMZ is efficient in eradicating B. pertussis
from the nasopharynx (Henry RL et al 1981),(Hoppe JE et al. 1989). TMP-SMZ is used as an alternative to a macrolide antibiotic
in patients aged >2 months who have a contraindication to or cannot tolerate macrolide agents, or who are infected with a
macrolide-resistant strain of B. pertussis. Macrolide-resistant B. pertussis is rare. In light of the potential hazard for kernicterus
among newborn children, TMP-SMZ ought not to be managed to pregnant ladies, nursing moms, or babies matured <2 months.
Recommended regimen:
• Infants matured <2 months: Contraindicated.
• Infants matured >2 months and youngsters: trimethoprim 8 mg/kg every day, sulfamethoxazole 40 mg/kg every day in 2
partitioned portions for 14 days.
• Adults: trimethoprim 320 mg for every day, sulfamethoxazole 1,600 mg for each day in 2 isolated dosages for 14 days.
Patients getting TMP-SMZ may encounter gastrointestinal unfriendly impacts, touchiness skin responses, and infrequently,
Stevens-Johnson disorder, lethal epidermal necrolysis, blood dyscrasias, and hepatic putrefaction. TMP-SMZ is contraindicated if
there is known excessive touchiness to trimethoprim or sulfonamides. TMP-SMZ ought to be recommended with an alert to
patients with debilitated hepatic and renal capacities, folate inadequacy, blood dyscrasias, and in more established grown-ups on
account of the higher rate of serious unfriendly occasions. Patients taking TMP-SMZ ought to be tell to keep up a satisfactory
liquid admission to anticipate crystalluria and renal stones. Medication connections must be viewed as when TMP-SMZ is
utilized associatively with medications, including methotrexate, oral anticoagulants, antidiabetic operators, thiazide diuretics,
anticonvulsants, and other antiretroviral drugs. TMP-SMZ is grouped by FDA as a Pregnancy Category C sedate (CDC.
Diphtheria, lockjaw, and pertussis: suggestions for antibody utilize and other preventive measures, 1991). Creature multiplication
contemplates have demonstrated an antagonistic impact on the fetus; No satisfactory or all around controlled examinations in
people exist.
E. Other antimicrobial agents- Despite the fact that in vitro movement against B. pertussis has been exhibited for different
macrolides, for example, roxithromycin and ketolides (e.g., telithromycin), no distributed information exists on the clinical
adequacy of these operators.
Other antimicrobial operators, for example, ampicillin, amoxicillin, antibiotic medication, chloramphenicol, fluoroquinolones
(e.g., ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin), and cephalosporins show different dimensions of in vitro inhibitory
movement against B. pertussis, yet in vitro inhibitory movement does not foresee clinical viability.The clinical effectiveness of
these agents for the treatment of pertussis has not been demonstrated. For instance, both ampicillin and amoxicillin were
ineffectual in clearing B. pertussis from nasopharynx (Trollfors B, 1978). Poor entrance into respiratory emissions was proposed
as a conceivable instrument for inability to clear B. pertussis from the nasopharynx (Hoppe JE et al 1988). The minimum
inhibitory concentration of B. pertussis to the cephalosporins is unacceptably high (Hoppe JE et al 1988). Likewise, antibiotic
medications, chloramphenicol, and fluoroquinolones have possibly unsafe symptoms in kids. Subsequently, nothing from what
was just mentioned antimicrobial operators are prescribed for treatment or postexposure prophylaxis of pertussis. (Recommended
Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines, 6/12/2017.
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5414a1.htm#tab4 9/19)
7.6 Médecins Sans Frontières, Clinical guidelines - Diagnosis and treatment manual. Paris 2016
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 394
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
Table 1- Recommendations of the US Centers for Disease Control and Prevention for antibiotic prophylaxis in close contacts of
patients with pertussis, regardless of vaccination status, to prevent health care-associated pneumonia
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 395
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
daily
erythromy
cin or
infants
aged more
than or
equal to 2
wk
twice daily
Table-2
once daily,
D2-D5 250 mg/day
for 5 days
III. ACKNOWLEDGMENT
On the occasion of presenting this article, It is my privilege to express my sincere thanks to my guide, mentor and supervisor
Dr. Meenakshi Dhanawat, M. M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala -
133207, Haryana, India, Who has provided excellent guidance, valuable advices, and shared intelligent thoughts, criticisms and
inculcated discipline. I am highly indebted to her for her valuable presence even in his busy schedule, which helped me to complete
this work successfully. I extend my profound respect and heartful gratitude to my beloved Parents Late. Rajendra Kumar Sharma
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 396
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
and Rajkumari. I also express my affection to my wife Deeksha and brother Kapil for their constant love, support, and
encouragement throughout my life.
We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no
significant financial support for this work that could have influenced its outcome.
REFERENCES
[1] A Complete Handbook of Nature Cure, Whooping Cough, http://www.healthlibrary.com/reading/ncure/chap101.htm (1 of 2)
[5/19/1999 9:37:10 PM], 14. http://www.healthlibrary.com/reading/ncure/chap101.htm (2 of 2) [5/19/1999 9:37:10 PM])
[2] A H Morice, L McGarvey, and I Pavord, Recommendations for the management of cough in adults, Thorax 2006;61(Suppl
I):i1–i24. doi: 10.1136/thx.2006.065144)
[3] Altunaiji S, Kukuruzovic R, Curtis N, et al; Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2007
Jul 18 (3):CD004404.
[4] Altunaiji S, Kukuruzovic R, Curtis N, Massie J (2007-07-18). "Antibiotics for whooping cough (pertussis)". Cochrane
database of systematic reviews (Online) (3): CD004404.
[5] Altunaiji S, Kukuruzovic R, Curtis N, Massie J., Antibiotics for whooping cough (pertussis).
https://www.ncbi.nlm.nih.gov/pubmed/15674946, PMID: 15674946 DOI: 10.1002/14651858.CD004404.pub2)
[6] American Academy of Pediatrics. Pertussis. In Pickering LK, editor. Red book 2003. Report of the Committee on Infectious
Diseases. 26th ed. Elk Grove Village (IL): The Academy; 2003. p. 472-86.
[7] American Academy of Pediatrics. Pertussis. In: Pickering L, Baker CJ, Kimberlin D, Long SS, eds Red Book: 2009 Report of
the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009:504–19.
[8] Antibacterial herbs of Ayurveda. https://ayurvedatreatments.co.in/ayurvedatreatments/index.php/ayurvedic-treatments/546-
antibacterial-herbs-of-ayurveda, 11/11/2018)
[9] Atkinson, William (May 2012). Pertussis Epidemiology and Prevention of Vaccine-Preventable Diseases (12 ed.). Public
Health Foundation. pp. 215–230.
[10] Ayurvedic Patent Medicines. https://ayurvedatreatments.co.in/ayurvedatreatments/index.php/ayurvedic-treatments/385-
ayurvedic-patent-medicines, 11/11/2018 )
[11] Ayurvedic treatment for Whooping Cough (Pertussis)
https://ayurvedatreatments.co.in/ayurvedatreatments/index.php/ayurvedic-treatments/325-ayurvedic-treatment-for-whooping-
cough-pertussis, 11/11/2018)
[12] Ayurvedic treatment of Whooping Cough. https://ayurvedatreatments.co.in/ayurvedatreatments/index.php/ayurvedic-
treatments/479-whooping-cough-and-its-ayurvedic-treatment, 11/11/2018)
[13] B. Siva Kumari, Y.T. Prabhu, Tambur Pavani, Traditional knowledge of medicinal plants used to cure respiratory diseases in
Krishna district of Andhra Pradesh, India. Journal of Medicinal Plants Studies, ISSN 2320-3862, 2014; 2(6): 34-37)
[14] Bace A, Zrnic T, Begovac J, Kuzmanovic N, Culig J. Short-term treatment of pertussis with azithromycin in infants and
young children. Eur J Clin Microbiol Infect Dis 1999;18:296-8.
[15] Bannatyne RM, Cheung R. Antimicrobial susceptibility of Bordetella pertussis strains isolated from 1960 to 1981.
Antimicrob Agents Chemother 1982;21:6667.
[16] Bass JW. Erythromycin for treatment and prevention of pertussis. Pediatr Infect Dis J 1986;5:154-7.
[17] Bergquist SO, Bernander S, Dahnsjo H, Sundelof B. Erythromycin in the treatment of pertussis: a study of bacteriologic and
clinical effects. Pediatr Infect Dis J 1987; 6 (5): 458–61.
[18] Birkebaek NH, Kristiansen M, Seefeldt T, et al. Bordetella pertussis and chronic cough in adults. Clin Infect Dis 1999;
29:1239–42.
[19] Boericke, W: Pocket Manual of Homeopathic Materia Medica and Repertory, B. Jain Publishers, New Delhi, 1929).
[20] Bortolussi R, Miller B, Ledwith M, et al. Clinical course of pertussis in immunized children. Ped Infect Dis J 1995;14:8704.
[21] Bruss JB, Malley R, Halperin S, Dobson S, Dhalla M, McIver J, et al. Treatment of severe pertussis: a study of the safety and
pharmacology of intravenous pertussis immunoglobulin. Pediatr Infect Dis J 1999;18:505-11.
[22] Carbonetti NH (June 2007). "Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease". Curr
Opin Pharmacol 7 (3): 272 -8. http://www.sciencedirect.com/science/article/pii/S1471489207000598
[23] CDC. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures: recommendations
of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991;40(No. RR10).
[24] CDC. Guidelines for the control of pertussis outbreaks. Atlanta, GA: US Department of Health and Human Services, CDC;
2000. Available at http://www.cdc.gov/nip/publications/pertussis/guide.htm.
[25] CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis. 2005 CDC
Guidelines. MMWR 2005;54(No. RR-14):1–16.
[26] Cherry JD, The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology
of Bordetella pertussis infection. Pediatrics 2005;115:1422–7.
[27] Dodhia H, Crowcroft NS, Bramley JC, Miller E. UK guidelines for use of erythromycin chemoprophylaxis in persons
exposed to pertussis. J Public Health Med 2002;24:200-6.
[28] Dodhia H, Miller E. Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis.
Epidemiol Infect 1998;120:143-9.
[29] DoucetPopulaire F, Pangon B, Doerman HP, Boudjadja A, Ghnassia JC. In vitro activity of a new fluroquinolone BAY
128039 in comparison with ciprofloxacin and macrolides against Bordetella pertussis.In: Programs and abstracts of the 37th
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 397
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28October 1,
1997 (Abstract F145: 170).
[30] Dr .Didier Grandgeorge, Homeopathic treatment of Cough, 27 November 2014)
[31] F. humphreys, M.D, homeopathic manual, the Office of the Librarian of Congress, at Washington. 1884)
[32] Familiar Ayurvedic herb and its uses. https://ayurvedatreatments.co.in/ayurvedatreatments/index.php/ayurvedic-
treatments/287-familiar-ayurvedic-herb-and-its-uses, 11/11/2018)
[33] Felmingham D, Robbins MJ, Leakey A, et al. The comparative in vitro activity of HMR 3647, a ketolide antimicrobial,
against clinical bacterial isolates. In: Programs and abstracts of the 37th Interscience Conference on Antimicrobial Agenta and
Chemotherapy, Toronto, Ontario, Canada, September 28October 1, 1997 (Abstract F116: 166).
[34] Friedman DS, Curtis RC, Schauer SL, et al. Surveillance for transmission and antibiotic adverse events among neonates and
adults exposed to a healthcare worker with pertussis. Infect Control Hosp Epidemiol 2004;25:96773.
[35] Gabrielle Traub, Natural Treatments for Coughs, Colds and Flu, 2006. www.SanDiegoHomeopathy.com)
[36] Galdi E, Moscato G. Pertussis in the aetiology of chronic cough in adults. Monaldi Arch Chest Dis 2002;57:229–30.
[37] Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect
Control Hosp Epidemiol 1996;17:5380.
[38] GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014)."Global, regional, and national age-sex
specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden
of Disease Study 2013.". Lancet 385 (9963): 117–71. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340604/
[39] Granstrom M, Olinder-Nielsen AM, Holmblad P, Mark A, Hanngren K. Specific immunoglobulin for treatment of whooping
cough. Lancet 1991;38:1230-3.
[40] Halperin SA, Bortolussi R, Langley JM, Miller B, Eastwood BJ. Seven days of erythromycin estolate is as effective as
fourteen days for the treatment of Bordetella pertussis infections. Pediatrics 1997;100:65-71.
[41] Hardy DJ, Hensey DM, Beyer JM Voktko c, McDonald EJ, Fennandes PB. Comparative in vitro activities of new 14, 15, and
16membered macrolides. Antimicrob Agents Chemother 1988;32:17109.
[42] Health and Homeopathy. www.healthandhomeopathy.com, 10/12/2018)
[43] Health Education Library For People. http://www.healthlibrary.com/reading/ncure/chap101.htm (2 of 2) [5/19/1999 9:37:10
PM])
[44] Heininger U (February 2010). "Update on pertussis in children". Expert review of anti-infective therapy 8 (2): 163–73.
[45] Henry R, Dorman D, Skinner J, et al. Limitations of erythromycin in whooping cough. Med J Aust 1981;2:1089.
[46] Henry RL, Dorman DC, Skinner J, et al. Antimicrobial therapy in whooping cough. Med J Aust 1981;2:278.
[47] Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with
erythromycin: a case review and cohort study. Lancet 1999;354:21015.
[48] Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L, et al. Infantile hypertrophic pyloric stenosis after
pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 1999;354:2101-5.
[49] Hoppe JE, Bryskier A. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides, (HMR
3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two
ansamycins (rifampin and rifapentine). Antimicrob Agents Chemother 1998;42:9656.
[50] Hoppe JE, Eichhorn A. Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis. Eur J Clin
Microbiol Infect Dis 1989;8:6534.
[51] Hoppe JE, Halm U, Hagedorn HJ, et al. Comparison of erythromycin ethylsuccinate and Cotrimoxazole For treatment of
pertussis. Infection 1989;17:22731.
[52] Hoppe JE. State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis. Infection
1998;26:2426.
[53] India, Ministry of Health and Family Welfare. The Ayurvedic formulary of India. Part II. New Delhi: Department of Indian
Systems of Medicine & Homeopathy, 2000. p. 49-56.
[54] India, Ministry of Health and Family Welfare. The Ayurvedic pharmacopoeia of India. Part I. Vol. IV. New Delhi:
Department of Indian Systems of Medicine & Homeopathy, 2004 p. 91-92.
[55] Irwin RS, Madison JM. The diagnosis and treatment of cough. N Engl J Med 2000; 343:1715-21.
[56] Klein J. Clarithromycin and azithromycin. Pediatr Infect Dis J 1998;17:516-7.
[57] Kurzinsky TA, Boehm DM, Rottpetri JA, Schell RF, Allison PE. Antimicrobial susceptibilities of Bordetella species isolated
in a multicenter pertussis surveillance project. Antimicrobn Agents Chemother 1988;32:13740.
[58] Kwantes W, Joynson HM, Williams WO. Bordetella pertussis isolation in general practice: 197779 whooping cough
epidemic in West Glamorgan. J Hyg Camb 1983;90:14958.
[59] Langley JM, Halperin SA, Boucher FD, Smith B; Pediatric Investigators Collaborative Network on Infections in Canada
(PICNIC). Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis.
Pediatrics 2004;114:e96-e101.
[60] Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective,
randomized, single blind trial. Pediatr Infect Dis J 2001;20:1149-54.
[61] Masruri. The secret of gurah therapy. Solo: CV Aneka Solo. 2000).
[62] Médecins Sans Frontières. Clinical guidelines - Diagnosis and treatment manual. Paris 2016 edition. ISBN 978-2-37585-001-
5
[63] Meenakshi Parihar, Ankit Chouhan, M.S. Harsoliya, J.K.Pathan, S. Banerjee, N.Khan, V.M.Patel. A Review- Cough &
Treatments, International Journal of Natural Products Research 2011;1 (1): 9-18 )
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 398
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
[64] Mikelova LK, Halperin SA, Scheifele D, Smith B, Ford-Jones E, Vaudry W, et al. Predictors of death in infants hospitalized
with pertussis: a case–control study of 16 pertussis deaths in Canada. J Pediatr 2003;143:576-81.
[65] Mortensen JE, Rodgers GL. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella
pertussis and Bordetella parapertussis. J Antimicrob Chemother 2000;45:479.
[66] National Center for Homeopathy. http://nationalcenterforhomeopathy.org/content/accelerating-the-healing-of-bone-fracture-
usinghomeopathy-a-prospective-randomized-double-b),
[67] National Center for Homeopathy. www.nationalcenterforhomeopathy.org/content/whooping-cough-back-in-the-news-
homeopathycan-)
[68] National consensus conference on pertussis, Toronto, May 25–28, 2002. Can Commun Dis Rep 2003;29(Suppl 3):1-33.
[69] National Treatment Guidelines for Antimicrobial Use in Infectious Diseases 2016, National Centre for Disease Control,
Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India)
[70] Pertussis (Whooping Cough) Causes & Transmission. cdc.gov. September 4, 2014. Retrieved 12 February 2015.
http://www.cdc.gov/pertussis/about/causes-transmission.html
[71] Pertussis (Whooping Cough) Complications. cdc.gov . August 28, 2013. Retrieved 12 February 2015.
http://www.cdc.gov/pertussis/about/complications.html
[72] Pertussis (Whooping Cough) Fast Facts. cdc.gov. February 13, 2014. Retrieved 12 February 2015.
http://www.cdc.gov/pertussis/fast-facts.html
[73] Pertussis (Whooping Cough) Signs & Symptoms. May 22, 2014. Retrieved 12 February 2015.
http://www.cdc.gov/pertussis/about/signs-symptoms.html
[74] Pertussis (Whooping Cough) Specimen Collection. cdc.gov . August 28, 2013. Retrieved 13 February 2015.
http://www.cdc.gov/pertussis/clinical/diagnostic-testing/specimen-collection.html
[75] Pertussis factsheet for healthcare professionals; Public Health England, August 2013
[76] Pichichero ME, Hoeger WJ, Casey JR. Azithromicin for the treatment of pertussis. Pediatr Infect Dis J 2003;22:847-9.
[77] Pierce C, Klein N, Peters M. Is leukocytosis a predictor of mortality in severe pertussis infection? Intensive Care Med
2000;26:1512-4.
[78] Pooboni S, Roberts N, Westrope C, Jenkins DR, Killer H, Pandya HC, et al. Extracorporeal life support in pertussis. Pediatr
Pulmonol 2003;36:310-5.
[79] Ranjit Roy Chaudhury, Uton Muchtar Rafei. Traditional Medicine in Asia. World Health Organization, Regional Office for
South-East Asia, New Delhi, 2001. ISBN 92 9022 2247)
[80] Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,
6/12/2017. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5414a1.htm#tab4 9/19
[81] Riitta H. The effect of early erythromycin treatment on the infectiousness of whooping cough patients. Acta Paediatr Scand
1982;298:1012.
[82] Romano MJ, Weber MD, Weisse ME, Siu BL. Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary
hypertension: improvement in oxygenation after a double volume exchange transfusion. Pediatrics 2004;114: e264-e266.
[83] Sharma PC, Yelne MB, Dennis TJ. Database on medicinal plants used in Ayurveda. Vol. 3. New Delhi: Central Council for
Research in Ayurveda & Siddha, New Delhi, 2001. p. 475.
[84] Sharma PC, Yelne MB, Dennis TJ. Database on medicinal plants used in Ayurveda. Vol. 3. New Delhi: Central Council for
Research in Ayurveda & Siddha, 2001. p. 473, 475.
[85] Sharma PC. Yelne MB, Dennis TJ. Database on medicinal plants used in Ayurveda. Vol. 3. New Delhi: Central Council for
Research in Ayurveda & Siddha, 2001. p. 474.
[86] Sprauer MA, Cochi SL, Zell ER, Sutter RW, Mullen JR, Englender SJ et al. Prevention of secondary transmission of
pertussis in households with early use of erythromycin. Am J Dis Child 1992; 146 (2): 177–81.
[87] Standard Treatment Guidelines For Medical Officers published: July 2003 Department Of Health & Family Welfare, GOC
With Support Of Chhattisgarh Basic Health Services Project Compiled And Prepared By: State Health Resource Centre,
Chhattisgarh (Additional Technical Capacity To Dohfw, A Joint Initiative Of Government Of Chhattisgarh & Action Aid
India))
[88] Standard Treatment Guidelines for pertussis, Republic of Ghana, Ministry of Health, Sixth Edition, 2010.
[89] Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices Advisory Committee.
Guidelines for preventing health-care–associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection
Control Practices Advisory Committee. MMWR Recomm Rep 2004;53(RR-3):1-36.
[90] Tozzi AE, Celentano LP, Ciofi degli Atti ML, Salmaso S., Diagnosis and management of pertussis. Tozzi et al, CMAJ •
FEB. 15, 2005; 172 (4))
[91] Tripathi KD. 2008. Essentials of Medical Pharmacology, 6th Ed. Jaypee Brothers Medical Publishers, New Delhi, India:
184-216.)
[92] Trollfors B. Effect of erythromycin and amoxycillin on Bordetella pertussis in the nasopharynx. Infection 1978;6:22830.
[93] US Food and Drug Administration. Current categories for drug use in pregnancy. Washington, DC: FDA Consumer
2001;35:3.
[94] Vermuelen, F: Concordant Materia Medica)
[95] Wang K, Bettiol S, Thompson MJ, et al; Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst
Rev. 2014 Sep 22 9:CD003257. doi: 10.1002/14651858.CD003257.pub5.
[96] Wang, K; Bettiol, S; Thompson, MJ; Roberts, NW; Perera, R; Heneghan, CJ; Harnden, A (22 September 2014).
"Symptomatic treatment of the cough in whooping cough.". The Cochrane database of systematic reviews 9: CD003257
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 399
© 2019 JETIR January 2019, Volume 6, Issue 1 www.jetir.org (ISSN-2349-5162)
[97] Wheeler JG, Tran TC, North P, Beavers-May T, Schutze GE, Snow SL. Barriers to public health management of a pertussis
outbreak in Arkansas. Arch Pediatr Adolesc Med 2004;158:146-52.
[98] Whooping cough treatment.
http://www.beyondconformity.org.nz/_blog/Hilary%27s_Desk/post/Whooping_cough_treatment/[6/14/12 9:35:43 AM])
[99] Whooping Cough, Dr Mary Harding, Document ID: 638 (v29), 6/12/2017 https://patient.info/in/doctor/whoopingcoughpro)
[100] Wilson KE, Cassiday PK, Popovic T, Sanden GN. Bordetella pertussis isolates with a heterogeneous phenotype for
erythromycin resistance. J Clin Microbiol 2002;40:2942-44.
[101] Wirsing von Konig CH, Postels-Multani S, Bogaerts H, Bock HL, Laukamp S, Kiederle S et al. Factors influencing the
spread of pertussis in households. Eur J Pediatr 1998; 157 (5): 391–4.
[102] Yao HH et al. [Clinical study on treatment of pertussis with acupuncture at baxie (EX:E9).] Chinese Acupuncture and
Moxibustion, 1996, 16(11):604 [in Chinese].)
JETIR1901148 Journal of Emerging Technologies and Innovative Research (JETIR) www.jetir.org 400